Nkarta Frames Lupus Plans, Cost Cuts Into A Pleasing Picture For Investors
Stock Rises On NK Cell Updates, Move Into Autoimmune Diseases
Nkarta framed a plan to extend its cash runway and fund key programs to value-creating milestones – including initiation of a lupus nephritis clinical trial – in a way that doubled the company’s stock price.
